← Back to Clinical Trials
Recruiting NCT06639932

NCT06639932 We-INtervention Among Chinese HIV-serodiscordant Male Couples

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06639932
Status Recruiting
Phase
Sponsor City University of Hong Kong
Condition HIV
Study Type INTERVENTIONAL
Enrollment 320 participants
Start Date 2025-09-01
Primary Completion 2027-04-30

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
We-INterventionUsual Care Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 320 participants in total. It began in 2025-09-01 with a primary completion date of 2027-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

HIV-serodiscordant male couples, in which one male partner is HIV-seropositive and the other is HIV-seronegative, experience multiple risks in HIV care and prevention. As stigma often hinders such couples' access to support and services, leveraging their relational resources is crucial for optimizing their outcomes. The proposed study will assess the efficacy of the three-session We-INtervention focusing on their relationship dynamics to enhance Chinese HIV-serodiscordant male couples' health and well-being. A total of 160 Chinese HIV-serodiscordant male couples (320 individuals: 160 HIV-seropositive and 160 HIV-seronegative) will be randomized at a 1:1 ratio to either the intervention or control arm. In the intervention arm, the We-INtervention will be delivered to both partners of each couple separately. In the control arm, each couple will receive health information pamphlets.

Eligibility Criteria

Inclusion criteria: 1. both partners are male, 2. both partners are aged 18 or above, 3. both partners report being in a committed relationship for at least 3 months, 4. one partner is HIV-seropositive and the other partner is HIV-seronegative (i.e., serodiscordant couple), 5. both partners have disclosed their serostatus to each other, and 6. both partners are willing to participate in this study. Exclusion criteria: 1. either partner is unable to complete the assessment due to a low education level or to physical or psychological constraints and 2. either partner has been diagnosed with another chronic disease (e.g., cancer and coronary heart disease).

Contact & Investigator

Central Contact

Nancy Xiaonan Yu, PhD

✉ nancy.yu@cityu.edu.hk

📞 34429436

Frequently Asked Questions

Who can join the NCT06639932 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06639932 currently recruiting?

Yes, NCT06639932 is actively recruiting participants. Contact the research team at nancy.yu@cityu.edu.hk for enrollment information.

Where is the NCT06639932 trial being conducted?

This trial is being conducted at Xiamen, China, Guangzhou, China, Shenzhen, China, Chengdu, China.

Who is sponsoring the NCT06639932 clinical trial?

NCT06639932 is sponsored by City University of Hong Kong. The trial plans to enroll 320 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology